ResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
Follow RMD
ResMed Inc. (RMD) EBITDA
ResMed Inc.'s EBITDA for fiscal 2026 was $2.1B, up 10.9% from $1.9B in fiscal 2025. Over the past ten years it has ranged from $482.3M (fiscal 2015) to $2.1B (fiscal 2026) — the current reading is the highest in ten years. EBITDA has risen for 11 consecutive fiscal years. ResMed Inc. ranks 6th of 50 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $2.1B | 10.91% |
| FY2025 | $1.9B | 25.07% |
| FY2024 | $1.5B | 15.55% |
| FY2023 | $1.3B | 11.33% |
| FY2022 | $1.2B | 9.03% |
| FY2021 | $1.1B | 10.51% |
| FY2020 | $991.0M | 35.75% |
| FY2019 | $730.1M | 10.32% |
| FY2018 | $661.8M | 23.02% |
| FY2017 | $538.0M | 4.30% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $503.8M | (11.43%) |
| Mar 2026 | $568.8M | 2.68% |
| Dec 2025 | $554.0M | 9.87% |
| Sep 2025 | $504.2M | (4.66%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MDLN Medline Inc. compare | $10.0B |
| BDX Becton, Dickinson and Company compare | $4.8B |
| ALC Alcon compare | $2.7B |
| SOLV Solventum Corporation compare | $2.6B |
| RMD ResMed Inc. | $2.1B |
| BAX Baxter International Inc. compare | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| WST West Pharmaceutical Services, Inc. compare | $861.8M |
| RGEN Repligen Corporation compare | $161.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RMD
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement